| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c500c6e58880b56b5cb1297f07876f25 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2013-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f1c9457d6d38f2dc18dc382f24f5533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5249257ed6562b48c74799ffa6f1193c |
| publicationDate |
2015-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015152503-A1 |
| titleOfInvention |
Micrornas for prediction of treatment efficacy and prognosis of cancer patients |
| abstract |
The present invention lies within the field of personalised medicine. More particular the invention relates to biomarkers useful for predicting treatment efficacy and prognosis in cancer patients. Thus the invention provides microRNAs (miRNAs) which are useful for predicting efficacy of anti-angiogenic treatment. In particular, miR-664 for the prediction of response to bevacizumab in colorectal cancer of sigmoid colon or rectum. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107236799-A |
| priorityDate |
2012-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |